Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

Prostate Cancer Clinical Trial

Official title:

Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00100243
• Other study ID #: 149-04-01
• Status: Completed
• Phase: Phase 2
• First received: December 27, 2004
• Last updated: September 18, 2006
• Start date: May 2004
• Est. completion date: September 2005

Study information

• Verified date: September 2006
• Source: PRAECIS Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled. Enrollment will be monitored to ensure that not all subjects are enrolled based on rising prostate specific antigen (PSA) criterion only.

Subjects will be treated with abarelix (Plenaxis) 100 mg intramuscularly (IM) every 2 weeks for 12 weeks (total dose of 600 mg).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: September 2005
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent

• Histologically or cytologically confirmed prostate cancer that has progressed within 60 days of the start of screening despite castrate levels of testosterone from treatment with an LHRH agonist. Progression will be defined as one or more of the following: *A rising PSA, defined as at least two consecutive rises in PSA over a reference value (PSA #1). The first rising PSA (PSA #2) must be taken at least one week after PSA #1. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2, OR

• The appearance of new metastatic lesions on a bone scan, OR

• Progression of known lesions or the appearance of new metastatic lesions on CT, MRI, chest x-ray, or other radiographic evaluations.

• Subject whose hormonal therapy includes an anti-androgen must have the anti-androgen discontinued prior to the start of screening (at least 6 weeks for bicalutamide and at least 4 weeks otherwise). If there is a reduction in the PSA after anti-androgen withdrawal, the subject must continue to demonstrate progression as defined above after anti- androgen withdrawal to be eligible.

• ECOG Performance Status = 3

• Age = 18 years of age

• Life expectancy = 6 months

• Serum testosterone less than or equal to 50 ng/dL

• PSA = 5 ng/mL (if progression is determined from a rise in PSA)

• WBC greater than or equal to 3,000/mm3

• Hematocrit = 30%

• Platelet count greater than or equal to 100,000/mm3

• Serum creatinine less than or equal to 2 x upper limit of normal (ULN)

• Bilirubin (direct or total) less than or equal to 2 x ULN

• SGPT (ALT) and SGOT (AST) less than or equal to 2 x ULN

Exclusion Criteria:

A subject is ineligible to participate in the study if he meets any of the following criteria:

• Prior treatment for prostate cancer with:

• Chemotherapy

• Radiopharmaceutical such as strontium or samarium

• Diethylstilbesterol or another estrogen agonist or antagonist

• Ketoconazole

• Aminoglutethimide

• Current treatment with Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medication

• Currently taking PC SPES

• History of allergy to a LHRH agonist or GnRH antagonist

• Major surgery within 4 weeks

• Serious medical illnesses, including malnutrition, that in the judgment of the investigator would preclude protocol treatment

• Significant cardiovascular illness defined as NYHA class III or IV congestive heart failure or unstable angina within 6 months, myocardial infarction within 12 months, deep venous thrombosis within 2 years, or any history of acute pulmonary embolism

• Active second malignancy other than non-melanoma skin cancer or superficial bladder cancer

• Any uncontrolled infection, including HIV

• Any other experimental therapy within 4 weeks prior to study entry

• QTc > 450 msec on a screening ECG obtained by the investigator

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Plenaxis

Locations

Country	Name	City	State
United States	Columbus Urology Research, LLC	Columbus	Ohio
United States	Southwest Florida Urological Associates	Fort Myers	Florida
United States	San Diego Center for Urology	La Mesa	California
United States	Urological Associates of Lancaster	Lancaster	Pennsylvania
United States	Carolina Urologic Research Center	Myrtle Beach	South Carolina
United States	Panama City Urological Center	Panama City	Florida
United States	Oregon Health & Science University	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
PRAECIS Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical adverse events, laboratory abnormalities, and withdrawals due to adverse events
Primary	Serum FSH levels below the lower limit of quantitation (LLOQ) on Days 57 and 85